Salute e Benessere
Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates
In the past two years, RSV has shifted from being an overlooked seasonal virus to one of the most aggressively targeted infectious diseases in the pharmaceutical pipeline. Major drivers shaping the market include:
GSK's Arexvy and Pfizer's Abrysvo-approved for adults ≥60 and pregnant women-have created a multi-billion-dollar opportunity in elder immunization and maternal immunization.
Nirsevimab (Sanofi/AstraZeneca) is disrupting infant protection with only , expanding coverage by 5x compared with earlier products like palivizumab.
An aging demographic, rising comorbidities, and viral seasonality shifts have increased hospital RSV admissions by in the U.S. and several Asian nations.
Multiple oral and inhaled antiviral candidates from global pharma companies aim to reduce severe RSV outcomes across all age groups.
Combined, these factors position RSV as the -second only to influenza.
Vaccines represented the largest segment in 2024, contributing of global revenue. Adult RSV vaccination and maternal immunization programs are expanding rapidly across the U.S., Japan , Europe , and select Asia-Pacific markets.
Monoclonal antibodies accounted for of the market. Nirsevimab's high-efficacy, single-dose seasonal protection has dramatically expanded infant immunization eligibility and uptake.
Antivirals held . Oral and inhaled antivirals remain essential for high-risk adults and immunocompromised patients, with strong pipeline potential expected to increase segment share by 2030.
This segment accounted for of 2024 global revenue.
Pediatric RSV remains the primary disease burden, with infants <6 months making up the majority of hospital admissions and ICU stays.
Adults represented , driven by new RSV vaccine approvals for older adults and immunocompromised populations.
The geriatric segment (aged ≥65) accounted for , reflecting high susceptibility to lower respiratory illnesses, severe complications, and hospitalization.
Hospital pharmacies captured of revenue as severe RSV cases-including infants and the elderly-are managed through hospital-based vaccination, monoclonal antibody programs, and inpatient antiviral administration.
Retail pharmacies represented , largely driven by adult RSV vaccinations delivered through community pharmacies, primary care clinics, and maternal immunization providers.
(
The U.S. accounted for of global RSV revenues in 2024.
The U.S. market is projected to exceed , driven by nationwide infant immunization programs and rapid pharmacy-based vaccination expansion.
Japan accounted for of global revenues in 2024.
Japan is projected to reach by 2033 as adult vaccine coverage accelerates.
(
The RSV therapeutics landscape is evolving faster than any other respiratory market. Key developments expected by 2033 include:
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/respiratory-syncytial-virus-market-to-reach-usd-4-54-billion-by-2033-as-global-uptake-of-next-generation-vaccines--monoclonal-antibodies-accelerates-302629123.html